These observations suggest that the increased immunoreactivity of TG2 in resveratrol-treated migratory SHYTG2 and pancreatic cancer cells is due to greater antigen accessibility of the anti-TG2 antibody to the Ca2+-sensitized open low migratory form of TG2. The gene discussed is TGM2; the disease is pancreatic neoplasm.